Advertisement
Jakafi (ruxolitinib) is the first drug approved to treat the rare bone marrow disease myelofibrosis, which causes bone marrow to be replaced by scar tissue. When the bone marrow scars, it may not be able to make enough blood cells, which can lead to bleeding, anemia and other problems. Jakafi is a pill that helps decrease scarring in the bone marrow and restore normal blood and immune system processes.
Continue Learning about Pharmacology
Important: This content reflects information from various individuals and organizations and may offer alternative or opposing points of view. It should not be used for medical advice, diagnosis or treatment. As always, you should consult with your healthcare provider about your specific health needs.